PACIRA BIOSCIENCES INC (PCRX:NASDAQ)
$25.9 0.14 (0.5435%)
Analysed PACIRA BIOSCIENCES INC (PCRX:NASDAQ) News Sources
Pacira BioSciences, Inc. Q2 2026 Earnings Call Summary
05-08-2026
moby.co
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
06-08-2026
yahoo.com
PharmaCorp Rx Inc. Announces Board and Committee Changes
27-08-2026
yahoo.com
MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
21-07-2026
yahoo.com
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
04-08-2026
yahoo.com
Pacira BioSciences Q2 Earnings Call Highlights
05-08-2026
marketbeat.com
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress
06-08-2026
yahoo.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07-08-2026
yahoo.com
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
10-08-2026
yahoo.com
Pacira (PCRX) Q2 2026 Earnings Call Transcript
12-08-2026
fool.com
What is the current price of PACIRA BIOSCIENCES INC (PCRX:NASDAQ)?
The current price of PACIRA BIOSCIENCES INC (PCRX:NASDAQ) is $25.9.
PACIRA BIOSCIENCES INC (PCRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of PACIRA BIOSCIENCES INC (PCRX:NASDAQ) since the previous trading day is $0.14.
PACIRA BIOSCIENCES INC (PCRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of PACIRA BIOSCIENCES INC (PCRX:NASDAQ) since the previous trading day is 0.5435%.
What is the most recent average sentiment score for PACIRA BIOSCIENCES INC (PCRX:NASDAQ)?
The most recent average sentiment score for PACIRA BIOSCIENCES INC (PCRX:NASDAQ) is 61 out of 100.
What is the most recent average sentiment for PACIRA BIOSCIENCES INC (PCRX:NASDAQ)?
The most recent sentiment for PACIRA BIOSCIENCES INC (PCRX:NASDAQ) is .
SEC-8K** Filing Available For PACIRA BIOSCIENCES INC (PCRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.